- In January 2024, Novo Nordisk entered into strategic collaborations with Omega Therapeutics and Cellarity to develop innovative therapies targeting cardiometabolic disorders. These partnerships aim to leverage cutting-edge technologies to accelerate the discovery of transformative treatments
- In January 2024, Eli Lilly and Company launched LillyDirect, a digital healthcare platform designed to streamline access to care for U.S. patients managing obesity, migraine, and diabetes. This initiative enhances patient support through online services and personalized treatment pathways
- In June 2023, the U.S. FDA approved VASCEPA capsules, the first prescription therapy comprised entirely of icosapent ethyl, a purified form of eicosapentaenoic acid. The approval represents a milestone in lipid management and cardiovascular risk reduction
- In October 2022, Eli Lilly and Company and Boehringer Ingelheim launched CRMSynced, an initiative aimed at encouraging healthcare professionals to adopt an integrated approach to managing cardio-renal-metabolic (C-R-M) conditions, recognizing the interconnection and shared disease pathways among the cardiovascular, renal, and metabolic systems
